Rémy Morgentin

<i>N</i>-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2<i>H</i>-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor

Laurent Hennequin, J M Allen, J. Breed et al. · Journal of Medicinal Chemistry · 2006 · 358 citations · Full text

Drug Target, Pharmacotherapy, Pharmaceutical Chemistry +16

Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases

Patrick A. Plé, Frédéric Jung, Sue Ashton et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 48 citations · Full text

Drug Target, Medicine, Rational Drug Design +8

Investigation of (<i>E</i>)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators

Sébastien L. Degorce, Andrew Bailey, Rowena Callis et al. · Journal of Medicinal Chemistry · 2015 · 42 citations · Full text

Breast Oncology, Female Reproductive Function, Pharmacotherapy +19

Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket

Peter Ballard, Robert H. Bradbury, Craig S. Harris et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 40 citations · Full text

Medicinal Chemistry, Biochemistry, Medicine +11

5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase

Peter Ballard, Robert H. Bradbury, Laurent Hennequin et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 34 citations · Full text

Medicinal Chemistry, Biochemistry, Medicine +10